UCB makes a rare acquisition
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Cytokinetics hopes to resurrect omecamtiv
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
